Sunday 18 October 2026 Export THMO’s income statement to Excel — free account

ThermoGenesis Holdings, Inc.

ThermoGenesis Holdings, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $9.4 million, down 9.90% from fiscal 2022. Operating cash flow growth for three consecutive years.

0.00 0.00 NaN

Follow THMO

Alert me

Market cap: $1.1M
P/E: 0.0×
Fwd P/E: 5.5×
Dividend yield: —
F-score: 3/9
Altman Z: −37.75
Beneish M: −9.50
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 12.82%

Capital & Financial Ratios $m

Market Cap 1.11

Revenue 9.61

Net Income (15.74)

Free Cash Flow (4.59)

Net Debt (1.18)

Current Ratio 0.52

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E 5.50

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 78.73%

Next Y EPS Growth 101.84%

Next Y revenue growth 182.69%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

EV/Sales against its own 10 years 48.88%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2021	2022	2023	Q'24
Cash	7	4	2	1
Receivables	1	2	1	1
Inventory	5	3	1	1
Other	—	—	—	—
	15	11	5	4

	2021	2022	2023	Q'24
Payables	1	1	1	1
ST’ Debt	—	—	—	—
Other	1	1	1	1
	6	12	12	8

Compound Annual Growth %

	10y	5y	3y
Sales	(5.16%)	(0.47%)	(1.03%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	3	—	—	—	—
’23	3	2	2	2	9
’22	3	3	2	3	10
’21	2	2	3	2	9
’20	3	2	2	2	10
’19	3	4	4	2	13
’18	2	2	3	3	10

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	—	—	—	—
’23	(1)	(1)	0	(2)	(4)
’22	(4)	(1)	(1)	(1)	(7)
’21	(4)	(1)	(1)	0	(7)
’20	(3)	(6)	(3)	(3)	(14)
’19	(2)	0	(1)	0	(3)
’18	(2)	(4)	(1)	0	(7)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	—	—	—	—
’23	(1)	(1)	0	(2)	(5)
’22	(4)	(1)	(1)	(1)	(8)
’21	(4)	(1)	(1)	0	(7)
’20	(3)	(6)	(3)	(3)	(14)
’19	(2)	(1)	(1)	0	(3)
’18	(2)	(5)	(1)	0	(8)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.46)	—	—	—	—
’23	(4.07)	(0.91)	(1.44)	(2.33)	(7.59)
’22	(7.21)	(9.01)	(4.50)	(0.10)	(20.45)
’21	(9.46)	(17.12)	(6.76)	(9.91)	(43.24)
’20	(50.00)	(45.95)	(16.67)	(10.81)	(117.12)
’19	(36.04)	(21.17)	(35.13)	(62.78)	(151.35)
’18	(121.62)	(779.28)	(54.05)	(67.57)	(972.97)

Fiscal quarters ending in the months shown.

Group	Line	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e
Price, $
Price, $	Low	—	—	737.10	1,179.00	94.50	105.75	73.35	43.46	2.67	0.51	Analyst estimates 2024–2026 Powerpack
	High	—	—	3,325.50	2,898.00	1,764.00	315.00	638.10	200.25	55.35	6.67
People
People	Employees	—	—	89	70	53	50	41	40	41	25
	Revenue/emp, $m	—	—	0.00	0.00	0.18	0.26	0.24	0.23	0.26	0.38
Income, $m
Income, $m	Revenue	—	—	12	12	10	13	10	9	10	9
	Gross margin, %	—	—	23.00	35.84	22.67	43.66	12.92	37.58	25.85	20.44
	EBT	—	—	(19)	(10)	(46)	(10)	(17)	(12)	(12)	(19)
	EBT margin, %	—	—	(155.82)	(83.29)	(472.19)	(77.40)	(172.53)	(127.82)	(112.68)	(200.31)
	Net income	—	—	(19)	0	(41)	(10)	(17)	(12)	(12)	(19)
	Depreciation	—	—	1	0	2	3	6	4	4	9
Per share, $
Per share, $	Revenue	—	—	48.57	534.49	236.48	207.75	69.90	35.46	19.03	3.99
	Earnings	—	—	(75.70)	(202.50)	(972.97)	(151.35)	(117.12)	(43.24)	(20.45)	(7.59)
	Cash flow	—	—	(39.19)	(147.42)	(170.73)	(51.91)	(103.25)	(25.26)	(13.22)	(1.57)
	Capex	—	—	0.00	0.00	(30.27)	(2.90)	(0.16)	(0.35)	(0.73)	(0.73)
	Free cash flow	—	—	(39.19)	(147.42)	(201.00)	(54.81)	(103.41)	(25.61)	(13.94)	(2.30)
	Book value	—	—	131.40	1,476.09	164.57	14.59	42.11	12.96	6.03	(1.51)
	Shares, m	—	—	0	0	0	0	0	0	1	2
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	2.34	2.23	0.51	0.95	1.35	1.28	0.19	0.14
	P/B	—	—	0.97	0.93	0.73	13.57	2.23	3.51	0.59	0.00
	EV/Sales	—	—	2.17	2.46	0.38	1.01	1.29	1.49	0.67	0.91
	EV/FCF	—	—	(1.96)	(4.85)	(0.45)	(3.84)	(0.87)	(2.07)	(0.92)	(1.57)
Cash, $m
Cash, $m	Operating cash flow	—	—	(10)	(3)	(7)	(3)	(14)	(7)	(7)	(4)
	Capex	—	—	(1)	0	(1)	0	0	0	0	(2)
	Free cash flow	—	—	(10)	(3)	(8)	(3)	(14)	(7)	(8)	(5)
Balance, $m
Balance, $m	Working capital	—	—	7	6	2	3	9	9	(1)	(7)
	Total debt	—	—	2	7	1	5	7	9	4	—
	Net debt	—	—	(3)	3	(1)	1	(1)	2	(4)	(2)
	Shareholders’ equity	—	—	32	33	7	1	6	3	3	(4)
Returns, %
Returns, %	ROA	—	—	(37.25)	(9.31)	(120.86)	(63.68)	(90.65)	(54.82)	(56.30)	(117.41)
	ROIC	—	—	0.00	0.00	(494.38)	(175.04)	(104.19)	(84.29)	0.00	0.00
	ROE	—	—	(57.60)	(14.26)	(198.86)	(248.38)	(481.90)	(245.58)	(335.42)	13,773.95

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2023 · latest quarter Mar 2024

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
VJET Flyte Aviation, Inc.	$2.1M	— (loss-making)	— (loss-making)	+380.66% (above 0%: growing)	n/m	−26.70% (below 0%: shrinking)	9.62%	(388.13%)	Compare
NUWE Nuwellis, Inc.	$2.0M	— (loss-making)	— (loss-making)	+14.14% (above 0%: growing)	n/m	−51.55% (below 0%: shrinking)	76.08%	(160.94%)	Compare
AFIB Acutus Medical, Inc.	$1.7M	— (loss-making)	— (loss-making)	+204.18% (above 0%: growing)	n/m	+76.40% (above 0%: growing)	14.20%	(3.81%)	Compare
DHAI DIH Holding US, Inc.	$1.6M	— (loss-making)	—	−30.67% (below 0%: shrinking)	n/m	−167.90% (below 0%: shrinking)	50.33%	(33.62%)	Compare
DYNTQ Dynatronics Corporation	$1.2M	— (loss-making)	— (loss-making)	−7.61% (below 0%: shrinking)	n/m	−193.04% (below 0%: shrinking)	24.65%	(1.26%)	Compare
THMO ThermoGenesis Holdings, Inc.	$1.1M	— (loss-making)	5.5×	+6.42% (above 0%: growing)	n/m	+62.12% (above 0%: growing)	43.92%	(20.35%)
SSKN Strata Skin Sciences, Inc.	$1.0M	— (loss-making)	— (loss-making)	−2.97% (below 0%: shrinking)	n/m	−376.88% (below 0%: shrinking)	61.82%	7.66%	Compare
FEED ENvue Medical, Inc.	$950.0K	— (loss-making)	— (loss-making)	−51.62% (below 0%: shrinking)	n/m	+19.75% (above 0%: growing)	(111.30%)	(2,290.38%)	Compare
PFSA PROFUSA, Inc.	$650.0K	0.0×	—	—	n/m	−359.25% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$1.4M	—	—	−2.97%	—	−109.72%	37.49%	(18.71%)

All 149 Medical Devices stocks →